The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).
 
Naureen Starling
Honoraria - Astellas Pharma; AstraZeneca; BMS; BMS; Daiichi Sankyo; GlaxoSmithKline; Merck; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Natera; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER; Tempus
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen; Moderna Therapeutics; MSD Oncology; Seagen; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; GlaxoSmithKline; Guardant Health; MSD Oncology; SERVIER; Takeda
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Igor Kiss
Consulting or Advisory Role - MSD Oncology
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BeiGene; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Eric Chen
Honoraria - AstraZeneca Canada; Eisai; GlaxoSmithKline; Merck; Pfizer; Roche; Takeda
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Repare Therapeutics; Roche Canada
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takata; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Gunnar Folprecht
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daichi; Exact Sciences; GlaxoSmithKline; Incyte; Janssen; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - Merck KGaA (Inst)
 
Go Kimura
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Merck; MSD; Nihonkayaku; Ono Yakuhin; Sanofi; Takeda
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Carole Flesch
Employment - Novartis; Roche (I)
Stock and Other Ownership Interests - Novartis; Roche (I)
Consulting or Advisory Role - Roche (I)
Patents, Royalties, Other Intellectual Property - Novartis (I)
 
Virginia Xu
Employment - Novartis
Stock and Other Ownership Interests - Lilly; Regeneron
 
Ana Bento Pereira da Silva
Employment - Novartis
Stock and Other Ownership Interests - Novartis; Roche
Travel, Accommodations, Expenses - Novartis
 
Rajan Sareen
Employment - IQVIA with a full-service provider role at Novartis
 
John Gregory
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO